Cost analysis of leuprorelin acetate in Japanese premenopausal breast cancer patients: Comparison between 6-month and 3-month depot formulations.
Cost analysis of leuprorelin acetate in Japanese premenopausal breast cancer patients: Comparison between 6-month and 3-month depot formulations.
复制标题
日本绝经前乳腺癌患者醋酸亮丙瑞林的成本分析：6 个月和 3 个月长效制剂的比较。
DOI：
10.1080/13696998.2017.1364647
复制
发表时间：
2017
影响因子：
2.4
通讯作者：
Kenta Takashima and Junichi Kurebayashi
中科院分区：
文献类型：
--
作者：
Rei Goto;Akihito Uda;Shinzo Hiroi;Kosuke Iwasaki;Kenta Takashima and Junichi Kurebayashi
目的：本研究的目的是从社会角度评价醋酸亮丙瑞林6个月贮库型制剂与醋酸亮丙瑞林3个月贮库型制剂在日本绝经前乳腺癌患者中的经济价值。方法：通过估计直接和间接成本以及与一次6个月注射相比两次3个月注射相关的无形成本进行成本分析。索赔数据用于分析直接和间接费用，直接费用采用医疗费用明细表。离散选择实验进行了基于网络的调查，以确定无形成本。另一项基于网络的调查也对注射醋酸亮丙瑞林的绝经前乳腺癌患者进行，以校准离散选择实验的结果。结果：在绝经前乳腺癌患者中，醋酸亮丙瑞林注射剂减少一次注射节省的医疗费用为6，183日元。生产力损失节省了1，419日元。少注射一次醋酸亮丙瑞林节省的无形成本估计为58，430日元，其中包括疼痛（8，535日元）、注射部位反应（44，051日元）、等待时间（9，595日元）和医疗咨询减值（3，751日元）导致的不利影响。减少一次注射节省的总成本为66，032日元。局限性：由调查公司提供的互联网小组的受访者不一定反映日本社会的人群。结论：醋酸亮丙瑞林6个月贮库型制剂通过节省医疗成本和生产力损失以及在治疗绝经前乳腺癌患者时减少一次注射节省的无形成本，证明了比醋酸亮丙瑞林3个月贮库型制剂更高的价值。在醋酸亮丙瑞林治疗成本中，无形成本的百分比可能不可忽略。无形成本可能会被积极评估，以推进以患者为中心的社会医疗保健。
Aims:The aim in this study is to evaluate economic value for leuprorelin acetate 6-month depot compared with leuprorelin acetate 3-month depot in Japanese pre-menopausal breast cancer patients from a societal perspective.Methods:The cost analysis was conducted by estimating direct and indirect cost, and intangible costs associated with one 6-month injection compared with two 3-month injections. Claims data were used for the analyses of direct and indirect cost and Medical Fee Schedule Table for direct cost. Discrete choice experiments were conducted by web-based survey to determine the intangible costs. Another web-based survey was also conducted on premenopausal breast cancer patients with injections of leuprorelin acetate, to calibrate the results of discrete choice experiments.Results:The medical costs saved for having one less injection in pre-menopausal breast cancer patients with leuprorelin acetate injection were JPY 6,183. The productivity loss saving was JPY 1,419. An estimation of intangible costs saved for having one less injection of leuprorelin acetate was JPY 58,430, which included the disbenefit due to pain (JPY 8,535), injection site reactions (JPY 44,051), waiting time (JPY 9,595), and subtracting value in medical consultation (JPY 3,751). The total cost saved for having one less injection was JPY 66,032.Limitations:The respondents from the internet panel provided by a survey company do not necessarily reflect a population of Japanese society.Conclusions:Leuprorelin acetate 6-month depot demonstrates a higher value than leuprorelin acetate 3-month depot through saving medical costs and loss of productivity, as well as intangible costs saved for having one less injection when treating pre-menopausal breast cancer patients. In the costs for treating with leuprorelin acetate, the percentage of intangible costs might not be negligible. The intangible costs will probably be actively evaluated to proceed to patient-centered healthcare in society.